Clinical Research Directory
Browse clinical research sites, groups, and studies.
Fabhalta Capsules Specified Drug-use Survey
Sponsor: Novartis Pharmaceuticals
Summary
The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.
Official title: Fabhalta Capsules Specified Drug-use Survey(C3 Glomerulopathy, CLNP023B11401)
Key Details
Gender
All
Age Range
0 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-09-17
Completion Date
2028-06-30
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Locations (23)
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Toyoake, Aichi-ken, Japan
Novartis Investigative Site
Chiba, Chiba, Japan
Novartis Investigative Site
Kitakyushu, Fukuoka, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Tsukuba, Ibaraki, Japan
Novartis Investigative Site
Komatsu, Ishikawa-ken, Japan
Novartis Investigative Site
Tsu, Mie-ken, Japan
Novartis Investigative Site
Nagasaki, Nagasaki, Japan
Novartis Investigative Site
Shimajiri-Gun, Okinawa, Japan
Novartis Investigative Site
Suita, Osaka, Japan
Novartis Investigative Site
Takatsuki, Osaka, Japan
Novartis Investigative Site
Kusatsu, Shiga, Japan
Novartis Investigative Site
Ohtsu, Shiga, Japan
Novartis Investigative Site
Shimotsuga Gun, Tochigi, Japan
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan
Novartis Investigative Site
Fuchū, Tokyo, Japan
Novartis Investigative Site
Nakano City, Tokyo, Japan
Novartis Investigative Site
Shinjuku Ku, Tokyo, Japan
Novartis Investigative Site
Yosa, Yosa, Japan
Novartis Investigative Site
Nara, Japan
Novartis Investigative Site
Wakayama, Japan